HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: jcp.2005.031377v1 59/9/947    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Song, Y-F Articles by Xie, Y Search for Related Content PubMed PubMed Citation Articles by Song, Y-F Articles by Xie, Y

High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma

¹ Department of Hematology, Hua Shan Hospital, Fu Dan University, Shanghai, China
² Center of Clinical Laboratory of Shanghai, Shanghai
³ Division of Internal Medicine, 3rd Peoples Hospital of Luohe, Luohe, China

Correspondence to:
Y-F Song
Department of Hematology, Hua Shan Hospital, Fu Dan University, 12 Wu Lu Mu Qi Zhong Road, Shanghai 200040, China; songyf03{at}yahoo.com Background: Deleted in liver cancer-1 (DLC-1) is a tumour suppressor gene that is inactive in liver carcinogenesis. It encodes a -guanosine triphosphatase-activating protein (-GAP) and maps to one of the deleted regions (8p21.3–22). Little is known, however, about the methylation status of the DLC-1 promoter in myeloma cells.

Aim: To identify whether methylation of DLC-1 was associated in pathogenesis of multiple myeloma.

Methods: Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect DLC-1 transcripts in RPMI 8226, U266, OPM-2 and XG-2 cell lines. The methylation status was determined by methylation-specific PCR followed by bisulphite DNA sequencing in these four cell lines and in the bone marrow of 14 patients with multiple myeloma and 4 normal patients. DLC-1 mRNA expression in cells with or without treatment with 5-aza-deoxycytidine (5-aza-CdR) or trichostatin A (TSA) was investigated by real-time RT-PCR.

Results: RPMI 8226 and U266 showed complete methylation and XG-2 showed partial methylation. DLC-1 was expressed only in OPM-2 cell lines that showed no methylation. DLC-1 methylation was shown in 11 of 14 (78%) patients with multiple myeloma and none of the normal controls. The exposure of cell lines to 5-aza-CdR or TSA resulted in the up regulation of DLC-1 gene expression.

Conclusions: DLC-1 methylation is often present in multiple myeloma and has a key role in DLC-1 silencing.

Abbreviations: 5-aza-CdR, 5-aza-deoxycytidine; CpG, cytosine-deoxyribose phosphates followed immediately by a guanine-deoxyribose phosphate; DLC-1, deleted in liver cancer-1 gene; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GTPase, guanosine triphosphatase; HCC, hepatocellular carcinoma; HDAC, histone deacetylase inhibitor; MSP, methylation-specific polymerase chain reaction; -GAP, -guanosine triphosphatase-activating protein; RT-PCR, reverse transcription-polymerase chain reaction; Tm, melting temperature; TSA, trichostatin A

This article has been cited by other articles:

				X. Qian, G. Li, H. K. Asmussen, L. Asnaghi, W. C. Vass, R. Braverman, K. M. Yamada, N. C. Popescu, A. G. Papageorge, and D. R. Lowy Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities PNAS, May 22, 2007; 104(21): 9012 - 9017. [Abstract] [Full Text] [PDF]

				Y.-C. Liao, L. Si, R. W. deVere White, and S. H. Lo The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1 J. Cell Biol., January 1, 2007; 176(1): 43 - 49. [Abstract] [Full Text] [PDF]